TScan Therapeutics
TCRX
60 hedge funds and large institutions have $32.8M invested in TScan Therapeutics in 2026 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 11 closing their positions.
7% more capital invested
Capital invested by funds: $30.7M → $32.8M (+$2.13M)
3.27% more ownership
Funds ownership: 58.5% → 61.77% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
2% less funds holding
Funds holding: 61 → 60 (-1)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.13M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$663K |
| 3 |
Two Sigma Investments
New York
|
+$596K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$361K |
| 5 |
D.E. Shaw & Co
New York
|
+$267K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$927K |
| 2 |
Jane Street
New York
|
-$261K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$169K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$109K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$62.9K |
TCRX Hedge Fund Activity: Q1 2026 in Review
60 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q1 2026, worth a combined $32.8M — up 6.9% from $30.7M a quarter earlier.
Fund positioning in TCRX was balanced in Q1 2026: 11 funds opened new positions, 11 closed out, 15 added to existing stakes and 20 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.13M. The largest seller was Aberdeen Group, cutting an estimated $927K.
- 60 institutional investors held TScan Therapeutics (TCRX) as of Q1 2026, down from 61 in Q4 2025.
- Funds reported $32.8M of TScan Therapeutics stock for Q1 2026, up 6.9% quarter-over-quarter.
- 11 funds opened new TScan Therapeutics positions in Q1 2026 and 11 closed out, a net change of 0 holders.
- The largest TScan Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $1.13M added.
- The largest TScan Therapeutics seller in Q1 2026 was Aberdeen Group, an estimated $927K sold.
Based on aggregated 13F filings for Q1 2026.